1. Home
  2. FFWM vs MLYS Comparison

FFWM vs MLYS Comparison

Compare FFWM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Foundation Inc.

FFWM

First Foundation Inc.

HOLD

Current Price

$6.22

Market Cap

521.3M

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.67

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFWM
MLYS
Founded
1990
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
521.3M
3.1B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
FFWM
MLYS
Price
$6.22
$37.67
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$6.17
$47.33
AVG Volume (30 Days)
642.6K
1.6M
Earning Date
01-29-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$159,621,000.00
N/A
Revenue This Year
$166.48
N/A
Revenue Next Year
$6.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47.55
N/A
52 Week Low
$4.42
$8.24
52 Week High
$6.47
$47.65

Technical Indicators

Market Signals
Indicator
FFWM
MLYS
Relative Strength Index (RSI) 66.10 44.37
Support Level $6.00 $36.01
Resistance Level $6.41 $38.40
Average True Range (ATR) 0.18 1.80
MACD 0.03 0.02
Stochastic Oscillator 77.78 42.69

Price Performance

Historical Comparison
FFWM
MLYS

About FFWM First Foundation Inc.

First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: